Template:Congestive heart failure: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 154: Line 154:
!
!
Medical Therapy:
Medical Therapy:
: [[Congestive heart failure pharmacotherapy|Summary]]
: [[Congestive heart failure acute pharmacotherapy|Acute Pharmacotherapy]]
: [[Congestive heart failure acute pharmacotherapy|Acute Pharmacotherapy]]
: [[Congestive heart failure chronic pharmacotherapy|Chronic Pharmacotherapy]]  
: [[Congestive heart failure chronic pharmacotherapy|Chronic Pharmacotherapy]]  
:: [[Congestive heart failure classification#Classification of Heart Failure Based on the Ejection Fraction (EF)|HFpEF]]:
:: [[Congestive heart failure diuretics|Diuretics]]
:: [[Congestive heart failure classification#Classification of Heart Failure Based on the Ejection Fraction (EF)|HFrEF]]:
:: [[Congestive heart failure ACE inhibitors|ACE Inhibitors]]
::: [[Congestive heart failure diuretics|Diuretics]]
:: [[Congestive heart failure angiotensin receptor blockers|Angiotensin receptor blockers]]
::: [[Congestive heart failure ACE inhibitors|ACE Inhibitors]]
:: [[Congestive heart failure aldosterone antagonists|Aldosterone Antagonists]]
::: [[Congestive heart failure angiotensin receptor blockers|Angiotensin receptor blockers]]
:: [[Congestive heart failure beta blockers|Beta Blockers]]
::: [[Congestive heart failure aldosterone antagonists|Aldosterone Antagonists]]
:: [[Congestive heart failure calcium channel blockers|Ca Channel Blockers]]
::: [[Congestive heart failure beta blockers|Beta Blockers]]
:: [[Congestive heart failure vasodilators|Nitrates]]
::: [[Congestive heart failure calcium channel blockers|Ca Channel Blockers]]
:: [[Congestive heart failure vasodilators|Hydralazine]]
::: [[Congestive heart failure vasodilators|Nitrates]]
:: [[Congestive heart failure positive inotropics|Positive Inotropics]]
::: [[Congestive heart failure vasodilators|Hydralazine]]
:: [[Congestive heart failure anticoagulants|Anticoagulants]]
::: [[Congestive heart failure positive inotropics|Positive Inotropics]]
:: [[Congestive heart failure angiotensin receptor-neprilysin inhibitor|Angiotensin Receptor-Neprilysin Inhibitor]]
::: [[Congestive heart failure anticoagulants|Anticoagulants]]
:: [[Congestive heart failure antiarrhythmic Drugs|Antiarrhythmic Drugs]]
::: [[Congestive heart failure angiotensin receptor-neprilysin inhibitor|Angiotensin Receptor-Neprilysin Inhibitor]]
:: [[Congestive heart failure other pharmacotherapies#Nutritional Supplements|Nutritional Supplements]]
::: [[Congestive heart failure antiarrhythmic Drugs|Antiarrhythmic Drugs]]
:: [[Congestive heart failure other pharmacotherapies#Hormonal Therapies|Hormonal Therapies]]
::: [[Congestive heart failure other pharmacotherapies#Nutritional Supplements|Nutritional Supplements]]
::: [[Congestive heart failure other pharmacotherapies#Hormonal Therapies|Hormonal Therapies]]
:[[Congestive heart failure drugs to avoid|Drugs to Avoid]]
:[[Congestive heart failure drugs to avoid|Drugs to Avoid]]
:[[Congestive heart failure drug interactions|Drug Interactions]]
:[[Congestive heart failure drug interactions|Drug Interactions]]

Revision as of 15:33, 27 October 2016

Congestive Heart Failure Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Causes

Differentiating Congestive heart failure from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Clinical Assessment

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Cardiac MRI

Echocardiography

Exercise Stress Test

Myocardial Viability Studies

Cardiac Catheterization

Treatment

Invasive Hemodynamic Monitoring

Medical Therapy:

Summary
Acute Pharmacotherapy
Chronic Pharmacotherapy
Diuretics
ACE Inhibitors
Angiotensin receptor blockers
Aldosterone Antagonists
Beta Blockers
Ca Channel Blockers
Nitrates
Hydralazine
Positive Inotropics
Anticoagulants
Angiotensin Receptor-Neprilysin Inhibitor
Antiarrhythmic Drugs
Nutritional Supplements
Hormonal Therapies
Drugs to Avoid
Drug Interactions
Treatment of underlying causes
Associated conditions

Exercise Training

Surgical Therapy:

Biventricular Pacing or Cardiac Resynchronization Therapy (CRT)
Implantation of Intracardiac Defibrillator
Ultrafiltration
Cardiac Surgery
Left Ventricular Assist Devices (LVADs)
Cardiac Transplantation

ACC/AHA Guideline Recommendations

Initial and Serial Evaluation of the HF Patient
Hospitalized Patient
Patients With a Prior MI
Sudden Cardiac Death Prevention
Surgical/Percutaneous/Transcather Interventional Treatments of HF
Patients at high risk for developing heart failure (Stage A)
Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)
Patients with current or prior symptoms of heart failure (Stage C)
Patients with refractory end-stage heart failure (Stage D)
Coordinating Care for Patients With Chronic HF
Quality Metrics/Performance Measures

Implementation of Practice Guidelines

Congestive heart failure end-of-life considerations

Specific Groups:

Special Populations
Patients who have concomitant disorders
Obstructive Sleep Apnea in the Patient with CHF
NSTEMI with Heart Failure and Cardiogenic Shock

Congestive heart failure On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Congestive heart failure

CDC on Congestive heart failure

Congestive heart failure in the news

Blogs on Congestive heart failure

Directions to Hospitals Treating Congestive heart failure

Risk calculators and risk factors for Congestive heart failure